You can buy or sell SNNA and other stocks, options, ETFs, and crypto commission-free!
Sienna Biopharmaceuticals, Inc. Common Stock, also called Sienna Biopharmaceuticals, is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Read More Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.
Westlake Village, California
52 Week High
52 Week Low
Sienna Biopharmaceuticals to Present at BAML Health Care Conference
WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference 2019, Wednesday, May 15, 2019, 3:55 p.m. PDT, in Las Vegas. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company's website at Investors.SiennaB...
Yahoo FinanceApr 27
Introducing Sienna Biopharmaceuticals (NASDAQ:SNNA), The Stock That Tanked 90%
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to avoid stomach churning catastrophes, wherever possible. It must have been painful to be a Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) shareholder over the last year, since the stock price plummeted 90% in that time. While some investors are willing to stomach this sort of loss, they are usually professionals who spread their bets thinly. Sienna Biopharmaceuticals may have better days ahead, o...
-$0.50 per share
-$0.67 per share